RA
RAC.AU Race Oncology Ltd
- Market cap
- AUD 303M
- P/E
- -
- P/B
- 8.31x
- ROE
- -30.4%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is RAC.AU undervalued?
Graham numberThe Graham number of Race Oncology Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Race Oncology Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-30.4%), below 10%.
ROA 1/1
Return on assets (-29.1%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-122.9%) is below the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 4.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (8.3x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Race Oncology Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Race Oncology Ltd
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and change…
Full company profileRace Oncology Ltd financial statements
Race Oncology Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 25.2K | 170K | 229K | 159K | 387K | 708K | 3.13M | 4.00M | 6.04M | - |
| Gross Profit | -250K | -80.6K | -52.7K | -122K | 106K | 427K | -281K | 2.22M | 5.41M | -281K |
| Operating Income | -4.04M | -6.33M | -3.76M | -3.96M | -6.48M | -11.5M | -13.0M | -17.8M | -3.77M | -12.4M |
| EBITDA | -3.93M | -6.23M | -3.61M | -3.72M | -6.45M | -11.6M | -12.8M | -14.2M | -4.43M | -12.2M |
| Net Income | -4.17M | -6.31M | -3.66M | -3.85M | -6.34M | -11.2M | -9.92M | -13.8M | -4.79M | -11.1M |
| EPS | -0.08 | -0.09 | -0.05 | -0.04 | -0.05 | -0.07 | -0.06 | -0.08 | -0.03 | -0.06 |
| Balance Sheet | ||||||||||
| Total Assets | 6.00M | 8.24M | 5.24M | 5.93M | 14.2M | 37.5M | 26.6M | 20.2M | 17.5M | 38.1M |
| Total Liabilities | 364K | 310K | 192K | 244K | 523K | 1.42M | 1.15M | 1.92M | 1.48M | 1.64M |
| Shareholders' Equity | 5.64M | 7.93M | 5.05M | 5.69M | 13.7M | 36.1M | 25.5M | 18.3M | 16.0M | 36.4M |
| Cash & Short-term Investments | 1.70M | 3.71M | 989K | 1.73M | 9.32M | 33.5M | 21.5M | 17.2M | 13.7M | 34.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.47M | -3.87M | -2.67M | -2.46M | -4.70M | -6.26M | -10.7M | -9.55M | -4.57M | -8.25M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 1.00 | 3.00 | 3.67K |
| Free Cash Flow | -2.47M | -3.87M | -2.67M | -2.46M | -4.70M | -6.26M | -10.7M | -9.55M | -4.57M | -8.25M |
| Ratios | ||||||||||
| ROE | -74.0% | -79.5% | -72.5% | -67.6% | -46.2% | -31.0% | -38.9% | -75.5% | -29.9% | -30.4% |
| ROA | -69.5% | -76.5% | -69.8% | -64.8% | -44.5% | -29.9% | -37.3% | -68.3% | -27.4% | -29.1% |
| Net Profit Margin | -16,549.0% | -3,703.7% | -1,601.3% | -2,413.2% | -1,636.6% | -1,582.6% | -316.6% | -345.2% | -79.2% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Race Oncology Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | AUD 533K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Race Oncology Ltd
- Insiders 27.08%
- Institutions 0.10%
- Public & others 72.82%
- Shares outstanding 196M
- Free float 136M
Race Oncology Ltd company profile
- Company name
- Race Oncology Ltd
- Ticker
- RAC.AU
- ISIN
- AU000000RAC3
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Gateway, 1 Macquarie Place, Sydney, NSW, Australia, 2000
- Phone
- 61 2 8051 3043
- Website
- racuraoncology.com
About Race Oncology Ltd
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Race Oncology Ltd management
6- Dr. Peter Michael Smith Ph.D.Executive Chairman · born 1963
- Dr. Daniel TillettCEO, MD & Director
- Mr. Brendan BrownChief Financial Officer
- Dr. Sophia MoscovisVice President of Operations & Strategy
- Dr. Jose L. Iglesias M.D.Chief Medical Officer · born 1957
- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · born 1963